Shares of iBio Inc. IBIO rose 5.14% to $3.07 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.28% to 20,009.34 ...

Canary Cure Therapeutics (Canary Global Inc.) has released preclinical results for its lead candidate, CCT-217, an siRNA therapeutic targeting cannabinoid CB1 receptor (CB1R) and zinc finger protein ...

Shares of iBio Inc. IBIO rose 3.18% to $2.92 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.64% to 19,756.78 ...

In a regulatory filing, iBio (IBIO) disclosed that its director Antonio Parada bought 183.8K shares of common stock on January 10th in a total ...

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, ...

Expected Phase 2 obesity data in Q2 2025 and Q4 2025 will shape clinical potential and development path of distinctive CB1 ...

SAN DIEGO - iBio Inc. (NYSEA: IBIO), whose stock has surged over 90% in the past year according to InvestingPro data, has announced, in partnership with AstralBio Inc., the creation of an antibody ...

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the ...

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in ...